Sander van Deventer, VectorY & Forbion | Pioneering gene therapy | E11

We’re in Amsterdam with Sander van Deventer, the CEO of VectorY. We will talk about VectorY and what’s missing in gene therapy. 💎 ABOUT THE SPEAKERSander has an impressive track record, being a professor, operational biotech founder and a VC. In 1998, he co-founded uniQure, which brought the first gene therapy to the market. He also co-founded the leading VC Forbion as well as Dezima. He is now building a new venture VectorY, again in gene therapy. I interviewed him in 2017 back at Labiotech so it’s great to catch up with him again. Top 50 Investors in Biotech in 2026: Europe’s Most Active Life Sciences Funds: https://flot.bio/european-biotech-investors-2026/ 📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/sander-van-deventer-gene-therapy/ 🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS[00:00:00] Intro [00:01:54] VectorY: Raising the largest Series A in 2023 in 🇪🇺[00:05:01] What's coming for ALS[00:07:50] How Vectorized Antibodies work[00:17:57] New Vector (AAV) technologies[00:22:55] The pipeline of VectorY[00:27:22] Where VC money is moving to[00:32:29] The Netherlands as a biotech cluster[00:35:31] CRISPR approval and gene therapy reimbursement[00:48:15] Where Sander came from[00:56:14] How to have the energy to be a serial entrepreneur